

Outpatient Medical Injectable Monoclonal Antibodies for the Treatment of Asthma and Eosinophilic Conditions Request Form Fax to 833-619-5745 (Medical Benefit Only)

Member Name:		
Member Date of Birth:		
Member UMI:		Medicare
Requesting Physician's Name:		NPI Number:
Requesting Physician's Address	:	
Office Contact:	Phone Number:	Fax Number:
Facility:		Facility NPI Number:
Facility's Address:		
Date of Service:		
Date of Service: \sigmas	upplied by Alliance Rx Walgred	ens Specialty Pharmacy □ Buy & Bill □ Other
FASENRA (J0517)	NUCALA (J2182)	CINQAIR (J2786) TEZSPIRE (J2356)
OTHER	(J)	
For Asthma:		
Does the member have SEVER	E Asthma? ☐ YES ☐ NO	
treatment?	ons has the patient had in t	he past 12 months requiring oral or systemic corticosteroid
• FEV1 (pre-bronchodila Please list any medications (ii		of test: njections) the member has been on over the past year for
asthma.		
• Name:		
• Name:		
Name:		
• Name:	Dose:	Duration (months):

Please verify member's eligibility and benefits through the health plan

Fax this completed form to Highmark at 1-833-619-5745

If YES, please provide:	a with an eosinophilic phenotype ? YES NO tcells/microliter		
Date of lab draw:	ttensymmeronter		
Will the requested product be used as add-on maintenance treatment? \square YES \square NO			
Will the requested product be ☐ YES ☐ NO	used <u>in combination with</u> Fasenra, Cinqair, Nucala, Tezspire, Xolair or Dupixent?		
	ed any of the following? <i>(circle all that apply)</i> asenra Cinqair Dupixent Tezspire		
-	ontraindications to the following? (circle all that apply) asenra Cinqair Dupixent Tezspire		
☐ New Start	☐ Continuation of Therapy		
	of the requested product has resulted in clinical improvement documented by: all that apply)		
	 □ Decreased utilization of rescue medications □ Decreased frequency of exacerbations 		
(Incl	☐ Increased predicted FEV1 from pretreatment baseline (Include baseline FEV1, Current FEV1)		
	☐ Reduction in reported asthma-related symptoms ☐ Decrease in ACQ-6 score by 0.5 or increase in ACT by 3 from pretreatment baseline		
	ill the requested product continue to be used as add-on maintenance therapy? YES \square NO		
Will the requested product be prescribed <u>in combination with</u> Fasenra, Nucala, Xolair, Cinqair or Dupixent? ☐ YES ☐ NO			
<u> </u>	atosis with Polyangitis (EGPA): *Nucala only		
	ory of relapsing disease? YES NO		
	age of oral prednisolone or prednisone for at least 4 weeks? ☐ YES ☐ NO standard of care while on Nucala (glucocorticoid with or without immunosuppressive		
therapy? ☐ YES ☐ NO			
☐ New Start	☐ Continuation of Therapy		
	Has treatment with Nucala resulted in an improvement of the member's		
	condition? ☐ YES ☐ NO		

Fax this completed form to Highmark at 1-833-619-5745

^{**}Please verify member's eligibility and benefits through the health plan**

For Hypereosinophilic Syndro	me (HFS): *Nucala only		
Has the member been diagnosed with HES for greater than or equal to 6 months? YES NO			
Is there an identifiable non-hematologic secondary cause of HES? YES NO			
Does the member have FIP1L1-PDGFRα kinase-positive HES? YES NO			
Has the member experienced at least 2 HES flares within the past 12 months? YES NO			
What is the member's baseline blood eosinophil count (prior to starting Nucala)? cells/microliter			
what is the member's baseline blood eosinophii count (phor to starting Nucaia):			
Is the member stable on HES therapy (corticosteroids, immunosuppressive or cytotoxic therapy) for at least 4 weeks			
before starting Nucala? ☐ YES ☐ NO			
☐ New Start	☐ Continuation of Therapy		
	Has treatment with Nucala resulted in decrease in HES flares? ☐ YES ☐ NO		
For Chronic Phinocipusitis with	th Nocol Dolume (CDS.v.NID). *Nucola only		
For Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): *Nucala only			
Will Nucala be used as add-on maintenance therapy? YES NO Has the member had inadequate results to pasal certificatoraids for at least 8 weeks of use (upless not talerated or			
Has the member had inadequate results to nasal corticosteroids for at least 8 weeks of use (unless not tolerated or contraindicated)? ☐ YES ☐ NO			
•	e following symptoms (check all that apply)		
The diagnosis is confirmed by the following symptoms (check all that apply)			
□ Nasal drainage			
□ Nasal blockage/obstruction/congestion□ Facial pressure or pain			
·			
☐ Decrease or loss in sense of smell lasting for at least 12 weeks			
Has the member been diagnosed with bilateral polyps of nasal endoscopy or CT scan? ☐ YES ☐ NO			
Provide the member's NPS (bilateral nasal polyp) score:			
Provide the member's VAS (visual analog scale) score:			
How many surgical procedures has the member had in the past 10 years for removal of nasal polyps?			
Will Nucala be used in combination with Fasenra, Cinqair, Tezspire, Xolair or Dupixent? ☐ YES ☐ NO			
☐ New Start	☐ Continuation of Therapy		
	Has treatment with Nucala resulted in improvement in signs and symptoms		
	documented by an improvement in VAS score? YES NO		
	Will Nucala be prescribed <i>in combination with</i> Fasenra, Nucala, Xolair, Cinqair or Dupixent? ☐ YES ☐ NO		
Please attach all pertinent clinical information			
Attached: VES NO			